

BAB 5

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan 7 jurnal terkait efektivitas dan efek samping Favipiravir pada pasien Covid-19 dapat disimpulkan bahwa :

1. Terapi Favipiravir dosis 1800 mg BID pada hari pertama diikuti 800 mg BID pada hari ke-2 hingga ke 14 dan terapi Favipiravir dosis 1600 mg BID pada hari pertama diikuti 600 mg BID pada hari ke-2 hingga ke 14 efektif dalam perbaikan klinis dan waktu pemulihan.
2. Efek samping yang terjadi pada pasien yang menerima terapi Favipiravir bergejala berat yaitu hiperurisemia 5,1%, fungsi hati abnormal 2,6%-43,2%, dan gangguan gastrointestinal 5,6%-10,9% serta pasien yang menerima terapi Favipiravir bergejala ringan hingga sedang yaitu hiperurisemia 5%-16,4%, fungsi hati abnormal meningkat 3-5 kali dari batas atas, dan gangguan gastrointestinal 0,8%-17,5%.

5.2 Saran

1. Berdasarkan hasil kajian literatur yang telah dilakukan disarankan perlu dilakukan penelitian lebih lanjut mengenai dosis Favipiravir pada pasien Covid-19 mengingat Favipiravir obat yang masih dikembangkan dalam terapi Covid-19 dan hasil penelitian yang terbatas.
2. Perlu dilakukan penelitian lebih lanjut mengenai efektivitas dan efek samping Favipiravir pada pasien Covid-19.

DAFTAR PUSTAKA

- Agrawal, U., Raju, R., & Udwadia, Z.F. 2020. Favipiravir: A New and Emerging Antiviral Option in COVID-19. *Medical Journal Armed Forces India*, **76(4)**: 370-376.
- Alamer, A., Alrashed, A.A., Alfaifi, M., Alosaimi, B., Alhassar, F., Almutairi, M., Howaidic, J., Almutairih, W., Mohzarid, Y., Sulaimani, T., Aljedaj, A., Alajamil, H.N., Alkhatjic, F., Alsaed, A., Alalin, A.H., Baredhwann, A.A., Abraham, I., Almulhim, A.S. 2021. Effectiveness and Safety of Favipiravir Compared to Supportive Care in Moderately to Critically Ill COVID-19 Patients: A Retrospective Study with Propensity Score Matching Sensitivity Analysis. *Current Medical Research and Opinion*, **37(7)**: 1085-1097.
- Almoosa, Z., Saad, M., Qara, S., Mustafa, M., Mansour, A., Alshab, D., Alhashemd, J., AlKhwajahe, S., Alkhalifahd, S., Almarzooqe, M., Alzaine, M., Anshasid, N., Ahmedf, G., Mutair, A.A. 2021. Favipiravir versus Standard of Care in Patients with Severe COVID-19 Infections: A Retrospective Comparative Study. *Journal of Infection and Public Health*, **14(9)**: 1247-1253.
- Azer, S.A. 2020. COVID-19: Pathophysiology, Diagnosis, Complications and Investigational Therapeutics. *New Microbes and New Infections*, **37(C)**: 1-8.
- Baker, J.D. 2016. The Purpose, Process, and Methods of Writing a Literature Review. *Association of Perioperative Registered Nurses journal*, **103(3)**:265-269.
- Bosaeed, M., Alharbi, A., Mahmoud, E., Alrehily, S., Bahlaq, M., Gaifer, Z., Alturkistani, H., Alhagan, K., Alshahrani, S., Tolbah, A., Musattat, A., Alanazi, M., Jaha, R., Sultana, K., Alqahtani, H., Aamer, K.A., Jaser, S., Alsaed, A., Ahmad, A., Abalkhail, M., Aljohani, S., Jerais, M. A., Almaziad, S., Albaalharith, N., Alabdulkareem, K., Alshowair, A., Alharbi, N.K., Arabiah, F., Alshamrani, M., Aldibasi, O., Alaskar, A. 2022. Efficacy of Favipiravir in Adults with Mild COVID-19: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial Clinical Trial. *Clinical Microbiology and Infection*. **28(4)**: 602-608.

- Burhan, E., Isbaniah, F., Susanto, A.D., Aditama, T. Y., Soedarsono., Sartono, T.R., Sugiri, Y.J., Tantular, R., Sinaga, B.Y. M., Handayani, R.R.D., Agustin, H., 2020, *Pneumonia COVID-19 Diagnosis dan Penatalaksanaan di Indonesia*, Jakarta : Perhimpunan Dokter Paru Indonesia.
- Burhan, E., Susanto, A.G., Nasution, S.A., Ginanjar, E., Pitoyo, C.W., Susilo, A., Firdaus, I., Santoso, A., Juzar, D.A., Arif, S.K., Wulung, N.G.H.L., Adityaningsih, D., Syam, F.A., Rasmin, M., Rengganis, I., Sukrisman, L., Damayanti, T., Aniwidyaningsih, W. H.W., Handayani, D., Soedarsono., Harsini., Sugiri, J.R., Afiatin, Wahyudi, E.R., Mulansari, N.A., Tarigan, T.J.E., Hidayat, R., Muchtar, F., Rumende, C.M., Soeroto, A.Y., Triyono, E.A., Katu, S., Agustina, P., Puspitorini, D., Wijaya, I.P., Nafrialdi., Musbah, T., Pulungan, A.B., Yanuarso, P.B., Pudjiadi., A.H., Sjakti, H.A., Alam, A., Kaswandani, N., Prawira, Y., Putri, N.D., Kadafi, K.T., Roeslaini, R.D., Sambo, C.M., Sugiarto, A., Pujo, B., Lubis, B., Pradian, E., Ismail, E., Hatin, F., Dharmawan, I. 2022. *Pedoman Tatalaksana Covid-19 Edisi 4*. Jakarta : Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) dan Ikatan Dokter Anak Indonesia (IDAI).
- Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C., & Napoli, R., 2022. *Features, Evaluation, and Treatment of Coronavirus (COVID-19)*. Statpearls. Tampa.
- Doi, Y., Hibino, M., Hase, R., Yamamoto, M., Kasamatsu, Y., Hirose, M., Mutoh, Y., Homma, Y., Terada, M., Ogawa, T., Kashizaki, F., Yokoyama, T., Koba, H., Kasahara, H., Yokota, K., Kato, H., Yoshida, J., Kita, T., Kato, Y., Kamio, T., Kodama, N., Uchida, Y., Ikeda, N., Shinoda, M., Nakagawa, A., Nakatsumi, H., Horiguchi, T., Iwata, M., Matsuyama, A., Banno, S., Koseki, D., Teramachi, M., Miyata, M., Tajima, S., Maeki, T., Nakayama, E., Taniguchi, S., Lim, C.K., Saijo, M., Imai, T., Yoshida, H., Kabata, D., Shintani, A., Yuzawa, Y., Kondo, M. 2020. A Prospective, Randomized, Open-Label Trial of Early Versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. *Antimicrobial Agents and Chemotherapy*. **64(12)** : 1-9.

- Du, Y.X., and Chen, X.P. 2020. Pharmacokinetics and Concerns about Clinical Trials for 2019-nCoV Infection. *Clinical Pharmacology Therapeutics*. **108(2)**: 242-247.
- Du, Z., Xu, X., Wu, Y., Wang, L., Cowling, B. J., & Meyers, L.A. 2020. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. *Emerging Infectious Diseases*. **26(6)**: 1341.
- Ivashchenko, A.A., Dmitriev, K.A., Vostokova, N.V., Azarova, V.N., Blinow, A.A., Egorova, A.N., Gordeev, I.G., Ilin, A.P., Karapetian, R.N., Kravchenko, D.V., Lomakin, N.V., Merkulova, E.A., Papazova, N.A., Pavlikova, E.P., Savchuk, N.P., Simakina, E.N., Sitdekov, T.A., Smolyarchuk, E.A., Tikhomolova, E.G., Yakubova, E.V., Ivachtchenko, A.V. 2021. AVIFAVIR for Treatment of Patients with Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of A Phase II/III Multicenter Randomized Clinical Trial. *Clinical Infectious Diseases*, **73(3)**: 531-534.
- Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., Barkate, H. 2021. Role of Favipiravir in the Treatment of COVID-19. *International Journal of Infectious Diseases*. **102**: 501-508
- Kaur, R.J., Charan, J., Dutta, S., Sharma, P., Bhardwaj, P., Sharma, P., Loguva, H., Krishnapillai, A., Islam, S., Haque, M., Misra, S. 2020. Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database. *Infection and Drug Resistance*, **13**: 4427-4438.
- Kementrian Kesehatan Republik Indonesia, 2020, *Pedoman Pencegahan dan Pengendalian Coronavirus Disease 2019 (COVID-19)*, Jakarta: Departemen Kesehatan Republik Indonesia.
- Manabe, T., Kambayashi, D., Akatsu, H., and Kudo, K., 2021. Favipiravir for the Treatment of Patients with COVID-19: A Systematic Review and Meta-Analysis. *BMC Infectious Diseases*. **21(1)**: 1-13.
- Mishima, E., Anzai, N., Miyazaki, M., and Abe, T. 2020. Uric acid Elevation by Favipiravir an Antiviral Drug. *The Tohoku Journal of Experimental Medicine*, **251(2)**: 87-90.
- Murti, B. 2013. Pengantar Evidence Based Medicine. Diakses pada 24 April 2020,

- National Institutes of Health, 2021, *Coronavirus Disease 2019 (COVID-19)*, U.S : Department of Health and Human Services.
- Onder, G., Rezza, G., & Brusaferro, S. 2020. Case-fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *Jama*. **323(18)**: 1775-1776.
- Pushkar, D. 2020. Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19. *Clinical Trials gov*: US National Library of Medicine.
- Samad, F., Saeed, Z., Hasan, Z. and Fahim, M.F. 2018, Evidence Based Medicine; Evidence Based Medicine Perceptions of Undergraduate Medical Students in Karachi, *The Professional Medical Journal*, **25(8)**: 896-902.
- Shinkai, M., Tsushima, K., Tanaka, S., Hagiwara, E., Tarumoto, N., Kawada, I., Hirai, Y., Fujiwara, S., Komase, Y., Saraya, T., Koh, ., Kagiya, N., Shimada, M., Kanou, D., Antoku, S., Uchida, Y., Tokue, Y., Takamori, M., Gon, Y., Ie, K., Yamazaki, Y., Harada, K., Miyao, N., Naka, T., Iwata, M., Nagakawa, A., Hiyama, H., Ogawa, Y., Shinoda, M., Ota, S., Hirouchi, T., Terada, J., Kawano, S., Ogura, S., Sakurai, T., Matsumoto, Y., Kunishima, H., Kobayashi, O., Iwata, S. 2021. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients Without Oxygen Therapy: A Randomized, Phase III Clinical Trial. *Infectious Diseases and Therapy*, **10(4)**: 2489-2509.
- Singh, T.U., Parida, S., Lingaraju, M.C., Kesavan, M., Kumar, D., & Singh, R.K. 2020. Drug Repurposing Approach to Fight COVID-19. *Pharmacological Reports*, **72(6)**: 1479-1508.
- Snyder, H., 2019, Literature Review as A Research Methodology: An Overview and Guidelines, *Journal of Business Research*, **104(C)**: 333-339.
- Solaymani, D.M., Ghanei, M., Bagheri, M., Qazvini, A., Vahedi, E., Saadat, S.H., Setarehdan, S.A., Ansarifard, A., Biganeh, H., Mohazzab, A., Khalili, D., Ghazale, A. H., Heidari, M. R., Taheri, A., Khoramdad, M., Asadi, M.M., Nazemieh, M., Varshochi M., Abbasian, S., Bakhtiari, A., Mosaed, R., Hosseini-shokouh, S., Shahrokhi, M., Yassin, Z., Zohal, M.A., Qaraati, M., Rastgoo, N.,

- Sami, R., Eslami, M.J., Asghari, A., Namazi, M., Ziaie, S., Jafari, M.R., Kalantari, S., Memarian, M., Khodadadi, J., Afshari, M.H., Momen, H.M., Behzadseresht, N., Mobayen, N.A.R., Mozafari, A., Movasaghi, F., Shoushtari, M.H., Moazen, J. 2021. Safety and Efficacy of Favipiravir in Moderate to Severe SARS-CoV-2 Pneumonia. *International Immunopharmacology*, **95**: 1-8.
- Steglitz, J. 2015, Evidence Based Practice, *International Encyclopedia of the Social & Behavioral Sciences*, **8**: 332-338.
- Udwadia, Z.F., Singh, P., Barkate, H., Patil, S., Rangwala, S., Pendse, A., Kadam, J., Wu, W., Caracta, C.F., Tandon, M. 2021. Efficacy and Safety of Favipiravir, an Oral RNA-dependent RNA Polymerase Inhibitor, in Mild to Moderate COVID-19: A Randomized, Comparative, Open Label, Multicenter, Phase 3 Clinical Trial. *International Journal of Infectious Diseases*, **103**: 62-71.
- Van, D.N., Bushmaker, T., Morris, D.H., Holbrook, M.G., Gamble, A., Williamson, B.N., Tamin, A., Harcourt, J.L., Gerber, S.I., Lloyd-Smit, J.O., Wit, E., Munster, V.J. 2020. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New England Journal of Medicine*. **382(16)**: 1564-1567.
- Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., Xiao, G. 2020. Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro. *Cell Research*. **30(3)**: 269–271.
- World Health Organization, 2022, *Coronavirus Disease 2019 (COVID-19)*, Switzerland: World Health Organization.
- Wu, Z., & Mcgoogan, J.M. 2020. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. *The Journal of the American Medical Association*. **323(13)**: 1239-1242.
- Yamazaki, S., Suzuki, T., Sayama, M., Nakada, T.A., Igari, H., and Ishii, I. 2021. Suspected Cholestatic Liver Injury Induced by Favipiravir in a Patient with COVID-19. *Journal of Infection and Chemotherapy*, **27(2)**: 390-392.